Sheffield, UK, November 2019 – Up to 20,000 patients in the UK will be taking part in the largest body of collective evidence in Europe. The study, named Project Twenty21, will be carried out by the independent scientific body, Drug Science. It is also backed by one of the leading medical bodies in the country – the Royal College of Psychiatrists.

Of the 20,000 patients to participate in the study, a large selection of conditions and illnesses will be represented. Project Twenty21 will assess the effects of Cannabis-based medical products on patients who suffer from chronic pain; epilepsy; multiple sclerosis; post-traumatic stress disorder; anxiety disorders; Tourette’s syndrome; and those with a history of substance misuse.
Access to medical Cannabis products has remained extremely low, despite the over a year of medical legalisation. Only 12 patients received a prescription for medical Cannabis, in the eight months following the law change.
Professor David Nutt from Drug Science claimed:
“Patients are left untreated, in significant debt from the cost of private prescriptions, or criminalised as they are forced to turn to the black market. They don’t deserve any of this, and the situation with prescribing desperately needs to change.”

Project Twenty21 will provide 20,000 patients with subsidised medical Cannabis products, in the hope of providing the desperately needed evidence. The Cannabis study will aim to convince policymakers that the drug should be made widely available as an alternative medication for a wide range of conditions.
Among the most quoted conditions said to benefit from medical Cannabis are chronic pain, multiple sclerosis, and rare forms of epilepsy. However, many people believe that the plant may be a viable option for many other conditions, including anxiety and depression disorders, and Dementias.
In the UK, around one in four people suffer from anxiety or depression. Prohibition Partners estimates that there are 52 conditions that are also potentially treatable with medical Cannabis. If this is the case, there may be 4 million patients who may benefit from easier access to medical Cannabis.
Why do you take CBD?
• FITNESS
• SPORTS
• WELLBEING
• PAIN MANAGEMENT
• ILLNESS
• OTHER
VOTE NOW
Would you like to know the results of our polls? Please complete the data request form by clicking here.

About Company:

We are Canex – the leading UK-based portal for CBD news. With the CBD industry exploding all around the world, we aim to bring you everything you need to know – from both home and abroad. The CBD industry has become one of the fastest growing health and wellness industries in recent years. We provide the most up-to-date information about the industry, in order to keep the general public well-educated in line with this growth.

From product news, reviews and guides; to legislation changes, industry updates and guides through the ongoing studies of the substance, Canex has it covered.

Here in the UK, the Cannabidiol industry is on the point of significant change, with calls coming from independent agencies for regulatory reform. Canex brings you all the information you need to know to the same place, making it easier to keep up to date than ever before.